Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
Open accessThe DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Insulin resistance and concurrent relative insulin deficiency and glucagon dysregulation underlie T2D pathophysiology.33–35”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alterations in these mechanisms lead to an increased fasting glucose production and impaired hepatic glucose uptake, contributing to the pathogenesis of type 2 diabetes (T2D) [1].”
From Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
The unique cytoarchitecture of human pancreatic islets has implications for islet cell function
Cabrera, O., Berman, D. M., Kenyon, N. S., Ricordi, C., Berggren, P.-O., & Caicedo, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510790103 · Cited by 1,312
Brüning, J. C., Michael, M. D., Winnay, J. N., Hayashi, T., Hörsch, D., Accili, D., Goodyear, L. J., & Kahn, C. R. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80155-0 · Cited by 1,182
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
(1922) · PubMed · Cited by 753
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Research works printed but not linked: 10
- Banting, 1922, Can Med Assoc J., 12, 141
- Cherrington, 1978, Biochem Soc Symp., 43, 31
- Exton, 1970, Recent Prog Horm Res., 26, 411
- Cherrington, 1979, Am J Physiol., 236, E263
- Davis, 1985, Am J Physiol., 248, E463
- Wada, 1995, Am J Physiol., 268, E194
- Holste, 1997, Am J Physiol., 273, E488
- Baum, 1962, Diabetes., 11, 371
- Meda, 1981, C R Seances Acad Sci III., 293, 607
- Cherrinton AD. Control of glucose production in vivo by insulin and glucagon. In:Handbook of Physiology . Vol. 2. 2011:759–785. · DOI · Paper page
Cited by
Items 501–600 of 682
Jiang, P., Zeng, Y., Yang, W. Y., Li, L., Zhou, L., Xiao, L., Li, Y., Gu, B., Li, X., Li, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116485 · Cited by 5
Dhaver, S., Al-Badri, M. R., Mitri, J., Askar, A., Mottalib, A., & Hamdy, O. (2025) · Nutrients · doi:10.3390/nu17132092 · Cited by 5
“In this study, although insulin increased after consumption of 2% milk, glucagon also increased, suggesting that the expected suppression may be blunted in T2D, or that the stimulatory effects of protein and fat override insulin’s inhibitory effect on glucagon [11].”
Åhrén, B., Galstyan, G. R., Gautier, J., Giorgino, F., Peralta, F. G., Krebs, M., Nikonova, E., Stager, W., & Vargas‐Uricoechea, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0179-6 · Cited by 5
“Such an effect may be achieved by a reduction in hepatic glucose production by the lowering of glucagon, as it is known that there is a linear relationship between portal glucagon levels and hepatic glucose production [14].”
BackgroundModeling the Amino Acid Effect on Glucagon Secretion from Pancreatic Alpha Cells
Zmazek, J., Grubelnik, V., Markovič, R., & Marhl, M. (2022) · Metabolites · doi:10.3390/metabo12040348 · Cited by 6
“Systemically, glucagon raises plasma glucose levels [2,57] by acting primarily on the liver glucagon receptors [28,58], counteracting the effects of insulin [59].”
BackgroundAssessment of a new model of glucagon action with glucagon receptor dynamics
Furió-Novejarque, C., Sanz, R., Reenberg, A. T., Ritschel, T. K. S., Ranjan, A. G., Nørgaard, K., Díez, J.-L., Jørgensen, J. B., & Bondía, J. (2022) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2022.09.169 · Cited by 5
Advances in natural small molecules on pretranslational regulation of gluconeogenesis
Wu, X., & Chen, S. (2023) · Drug Development Research · doi:10.1002/ddr.22053 · Cited by 5
“Metformin, one of the commonly used drugs for the treatment of T2DM, has been shown to activate AMPK to improve glucose homeostasis (Viollet et al., 2009), indicating that AMPK is an attractive drug target for the treatment of diabetes.”
BackgroundInfluentialCeramide enhanced the hepatic glucagon response through regulation of CREB activity
Wang, J., Wang, D., Lü, S., Hu, Y., Ge, Y., Qin, X., Mo, Y., Kan, J., Li, D., Zhang, R., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.12.008 · Cited by 6
Çetinkalp, Ş., Felekoglu, C., Karadeniz, M., Boyacıoğlu, H., Akçay, Y., Sözmen, E. Y., & Yılmaz, C. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.04.011 · Cited by 5
Аbramova, Т. V., & Kolesnyk, Y. M. (2017) · Pathologia · doi:10.14739/2310-1237.2017.2.109249 · Cited by 5
Tripartite cell networks for glucose homeostasis
Song, T., & Jo, J. (2019) · Physical Biology · doi:10.1088/1478-3975/ab2a9d · Cited by 6
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Gao, R., Acreman, S., Dou, H., Ma, J., MIRANDA, C. A., Zhao, R., Dickerson, M. T., Tarasov, A. I., Zou, Q., Gironella-Torrent, M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-025-01422-7 · Cited by 6
“Accurately orchestrated and reciprocal changes of islet hormones are required for systemic glucose homoeostasis 4 , and dysregulated secretion and action of islet hormones are hallmarks of diabetes 5–7 .”
Asadi, F., Gunawardana, S. C., Dolle, R. E., & Piston, D. W. (2024) · JCI Insight · doi:10.1172/jci.insight.172626 · Cited by 4
“Accordingly, a glucagon-centric hypothesis proposes that combating hyperglucagonemia can result in normalization of hyperglycemia in T1D (7).”
Ciarelli, J. N., Thangaraj, S. V., Sun, H., Domke, S., Alkhatib, B., Vyas, A. K., Gregg, B. E., Sargis, R. M., & Padmanabhan, V. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112202 · Cited by 4
Imeglimin suppresses glucagon secretion and induces a loss of α cell identity
Tsuno, T., Li, J., Nishiyama, K., Kawasawa, Y. I., Inoue, R., Yajima, E. O., Nishiyama, A., Yabe, S. G., Kin, T., Okochi, H., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102254 · Cited by 6
Disease, Models, Variants and Altered Pathways—Journeying RGD Through the Magnifying Glass
Petri, V., Hayman, G. T., Tutaj, M., Smith, J. R., Laulederkind, S. J. F., Wang, S., Nigam, R., Pons, J. D., Shimoyama, M. E., & Dwinell, M. R. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.11.006 · Cited by 5
“diet/environment interactions, andmicrobiota, in single and any combination of them, result in aberrant contributions to glucose levels and hyperglycemia? The contribution of glucagon to diabetes, that is glucagon excess, rather than insulin deficiency, has been proposed [16].”
BackgroundDesign, synthesis, and effects of novel phenylpyrimidines as glucagon receptor antagonists
Choi, H., Lee, C.-Y., Park, E., Lee, K. M., Shin, D., & Jun, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.10.013 · Cited by 4
Hashimoto, S. (2016) · Springer eBooks · doi:10.1007/978-4-431-55790-6_5 · Cited by 5
MEYTS, P. D., & Lefèbvre, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813814-4.00017-1 · Cited by 4
Impairments of insulin and glucagon sensitivity in Chinese women with gestational diabetes mellitus
Zhang, D., Zhu, J., Albrechtsen, N. J. W., Rayner, C. K., Saffery, R., Zhang, H., Chen, C., & Wu, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15740 · Cited by 4
“25 While impairments in insulin and glucagon sensitivity were common in Han Chinese women with GDM, there was only a weakly positive correlation between HOMA-IR and the glucagon-alanine index in the pooled analysis involving participants of both groups, with no significant correlation within either…”
Distributed aspects of the artificial pancreas
Patek, S. D., Chen, S., Keith-Hynes, P., & Lee, I. (2013) · Allerton Conference on Communication, Control, and Computing · doi:10.1109/allerton.2013.6736572 · Cited by 5
“…use frequent measurement of BG to alarm, advise, and/or automatically intervene in the treatment of diabetes with insulin, possibly also incorporating the use of other hormones (e.g. glucagon or amylin) and/or other sensing modalities (e.g. accelerometers or heart rate monitors) to improve control.”
BackgroundExpression, purification and preliminary characterization of glucagon receptor extracellular domain
Wu, L., Zhai, Y., Lu, J., Wang, Q., & Sun, F. (2013) · Protein Expression and Purification · doi:10.1016/j.pep.2013.04.004 · Cited by 4
“manifestations [5,6].”
Ridout, S. A., Vellanki, P., & Nemenman, I. M. (2025) · eLife · doi:10.7554/elife.100193 · Cited by 5
“On the other hand, due to the much lower relative concentration of insulin produced in the islets by exogenous insulin administration rather than endogenous insulin ( Unger and Cherrington, 2012 ), this seems unlikely.”
Advances in Small Molecules of Flavonoids for the Regulation of Gluconeogenesis
Wu, X., Wang, A., Ning, C., Wu, Y., & Chen, S. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230726145514 · Cited by 3
Himuro, M., Wakabayashi, Y., Taguchi, T., Katahira, T., Suzuki, L., Iida, H., Ogihara, T., Nishida, Y., Sasaki, S., Lynn, F. C., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-06028-w · Cited by 3
“Although the primary cause of diabetes is an absolute or relative deficiency of insulin-producing pancreatic beta cells, it has been known for decades that inappropriate glucagon secretion from alpha cells is involved in the pathophysiology of diabetes [4–6].”
BackgroundAdvances in clinical research on glucagon
Horie, I., & Abiru, N. (2024) · Diabetology International · doi:10.1007/s13340-024-00705-w · Cited by 3
“The lack of a suppression of postprandial glucagon secretion might be implicated in the postprandial hyperglycemia among individuals with T2D [34, 35].”
Non-functional alpha-cell hyperplasia with glucagon-producing NET: a case report
Cidade-Rodrigues, C., Santos, A. P., Calheiros, R., Santos, S., Matos, C., Moreira, A. P., Inácio, I. M. R., Souteiro, P., Oliveira, J., Jácome, M., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1405835 · Cited by 4
“Regarding the fi rst question, diabetes possibly being secondary to glucagon excess is a reasonable hypothesis since glucagon seems to be more critical for the development or worsening of diabetes than insulin de fi ciency (16 – 18).”
BackgroundLee, J., Ustione, A., Wilkerson, E., Balakrishnan, R., Thurmond, D. C., Goldfarb, D., & Piston, D. W. (2025) · Diabetes · doi:10.2337/db24-1003 · Cited by 5
Target Discovery to Diabetes Therapy—TXNIP From Bench to Bedside With NIDDK
Shalev, A. (2025) · Endocrinology · doi:10.1210/endocr/bqaf055 · Cited by 4
Allosteric communication mechanism in the glucagon receptor
van der Velden, W. J. C., Mukhaleva, E., & Vaidehi, N. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108530 · Cited by 3
“Recent research has shown that glucagon receptor agonism (in combination with glucagon-like peptide 1 receptor [GLP-1R] agonism) rather than antagonism is more promising as a therapeutic intervention of combating diabetes and other metabolic disorders (35 – 38).”
Ghorani, E., Evans, M. L., & Simmons, D. S. (2016) · Practical Diabetes · doi:10.1002/pdi.2001 · Cited by 3
A New Activator of Hepatocyte CaMKII in Fasting and Type 2 Diabetes
Özcan, L., & Tabas, I. A. (2018) · Diabetes · doi:10.2337/dbi18-0026 · Cited by 3
“Previous work had shown that PGF2a, which is formed from arachidonic acid via cyclooxygenase, is elevated in hepatocytes of both fasting and obese, insulin-resistant mice and that a PGF2a metabolite in the urine is increased in T2D patients (9,10).”
BackgroundInfluentialAdvances in basic research on glucagon and alpha cells
Hayashi, Y. (2024) · Diabetology International · doi:10.1007/s13340-024-00696-8 · Cited by 3
“If glucagon levels are increased due to the insufficient suppression of glucagon secretion and/or islet dysfunction as proposed in a glucagonocentric view of diabetes, the suppression of glucagon secretion and/or blocking glucagon activity seem to be appropriate therapeutic maneuvers [9].”
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6686-0_37 · Cited by 4
Wei, Z., Wang, M., Zhang, H., Wang, Z., Wang, G.-N., Wei, F., Zhang, Y., Xu, X., & Zhang, Y. (2018) · Medicine · doi:10.1097/md.0000000000013710 · Cited by 3
γ-Hydroxybutyrate does not mediate glucose inhibition of glucagon secretion
Yu, Q., Lai, B. K., Ahooghalandari, P., Helander, A., Gylfe, E., Gilon, P., & Tengholm, A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009577 · Cited by 3
“Moreover, diabetic patients frequently exhibit abnormally high postprandial glucagon release, contributing to hyperglycemia (2).”
BackgroundA tribute to Roger H. Unger (1924–2020)
Scherer, P. E., & Newgard, C. B. (2020) · Journal of Clinical Investigation · doi:10.1172/jci145796 · Cited by 4
“Perhaps most importantly, Roger put forth the idea that the glucagon/insulin ratio in blood is a critical determinant of fuel homeostasis and that diabetes is not just simply a disease of insulin deficiency, but one of unopposed glucagon action (referred to as “the bihor-monal hypothesis”) (3, 4).”
Kang, R. B., Lee, J., Varela, M., Li, Y., Rosselot, C., Zhang, T., Karaköse, E., Stewart, A. F., Scott, D. K., García-Ocaña, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.19.567715 · Cited by 3
Xu, S., Hayashi, Y., Takagishi, Y., Itoh, M., & Murata, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064415 · Cited by 2
“proliferation of a-cells and disregulated glucagon production have been recently highlighted in the pathogenesis of diabetes mellitus [23,24].”
BackgroundGPR41 and GPR43 modulate rodent pancreatic α-cell function and growth
Sánchez-Roncero, A., Fernández‐Marcelo, T., Perez-Serna, A. A., Martín, M. Á., Alberquilla, O., Sánchez‐Domínguez, R., Segovia, J. C., Escrivá, F., Gálvez, B. G., Álvarez, C., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123913 · Cited by 2
What Do Single-Cell Models Already Know About Perturbations?
Bjerregaard, A., Prada-Luengo, I., Das, V., & Krogh, A. (2025) · Genes · doi:10.3390/genes16121439 · Cited by 5
Zhao, T., Cen, J., Wang, X., Yang, M., Lau, J., Tengholm, A., Sjöholm, Å., & Welsh, N. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111336 · Cited by 2
Putman, M. S., Hull-Meichle, R. L., Waters, S. A., Tuggle, K. L., Sommer, P., Conway, R., Borthwick, L. A., Knudsen, J. G., Dean, E. D., Stanley, S. A., et al. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.03.021 · Cited by 2
Insulin/IGF signaling in islet biology and its therapeutic implications
Kim, H., & Kulkarni, R. N. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag014 · Cited by 2
Alpha cells as targets for incretin therapy
Lakhani, O. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_97_23 · Cited by 2
Modelling remission from overweight type 2 diabetes reveals how altering advice may counter relapse
Sweatman, C. Z. W. H. (2024) · Mathematical Biosciences · doi:10.1016/j.mbs.2024.109180 · Cited by 2
Lyngdoh, J., Chutia, H., Sundaram, S. P., Lakshmi, V., Ruram, A. A., & Lynrah, K. G. (2024) · Cureus · doi:10.7759/cureus.58942 · Cited by 3
Dissecting the actions of widely used diabetes drugs
Unger, R. H., Berglund, E. D., Habener, J. F., & Cherrington, A. D. (2013) · Nature Medicine · doi:10.1038/nm.3123 · Cited by 2
Self-citationBernsmeier, C., Meyer‐Gerspach, A. C., Blaser, L. S., Jeker, L., Steinert, R. E., Heim, M. H., & Beglinger, C. (2013) · Journal of Hepatology · doi:10.1016/s0168-8278(13)61317-3 · Cited by 2
Glucagon and the Glucagon-Like Peptides
Drucker, D. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00034-2 · Cited by 2
An overview of non-insulin adjunctive therapies for Type 1 diabetes
Ballav, C., & Gough, S. C. L. (2014) · Diabetes Management · doi:10.2217/dmt.14.38 · Cited by 2
Hu, L., Zhang, Y., Wang, H., Peng, X.-Y., & Wang, Y. (2016) · Chinese Chemical Letters · doi:10.1016/j.cclet.2016.05.023 · Cited by 2
Lineage conversion of mouse fibroblasts to pancreatic α-cells
Liu, T., Sun, L., Jiang, B., Li, L., Cen, J., Chen, X., Zhang, Z., Wang, Q., Cheng, X., Shi, Y., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.84 · Cited by 2
SGLT2 Inhibitors Therapy in Type 2 Diabetes Mellitus
Ahmad, M. M., Brema, I. A., & Almalki, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84152 · Cited by 3
Characterization of Protein-Metabolite and Protein-Substrate Interactions of Disease Genes
McFedries, A. (2014) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 2
Alpha-Cell Secretion Across the Spectrum of Glucose Tolerance
Salehi, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad686 · Cited by 2
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
“Glucagon opposes insulin actions in the liver; glucagon levels increase during states of low insulin levels, including during starvation or hypoglycemia and increase EGP [89].”
BackgroundHoussarini, J. A., Brnabic, A. J. M., & Obaid, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01184-x · Cited by 1
Іваненко, Т. В. (2022) · Current issues in pharmacy and medicine science and practice · doi:10.14739/2409-2932.2022.3.259868 · Cited by 1
Pixner, T., Chaikouskaya, T., Lauth, W., Zimmermann, G., Mörwald, K., Lischka, J., Furthner, D., Awender, E., Geiersberger, S., Maruszczak, K., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1368570 · Cited by 3
Du, J., Zhang, K., Miao, J., Yang, Y., Tian, Y., Wu, T., Tao, C., Wang, Y., & Yang, S. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123337 · Cited by 1
Deguchi, M., Hosoda, A., Fukumura, T., Saeki, S., & Kim, D.-H. (2025) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbaf133 · Cited by 1
Tanabe, H., Shimajiri, Y., Shiroma, K., Higa, M., Masuzaki, H., & Shimabukuro, M. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf654 · Cited by 1
Zhu, W., Pan, L., Cui, X., Russo, A. C., RAY, R., Pederson, B., Wei, X., Lin, L. L., Torres, M., Hafner, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69928-6 · Cited by 1
Tsvetkova, V. V., Todorova, M., Atanasova, M., Gencheva, I. I., & Todorova, K. N. (2026) · Diabetology · doi:10.3390/diabetology7040071 · Cited by 1
Ganamurali, N., Prabhakaran, M., & Sabarathinam, S. (2026) · Comprehensive physiology · doi:10.1002/cph4.70145 · Cited by 1
“This is reframed by the “glucagonocentric hypothesis,” which contends that systemic metabolic disorders and hyperglycemia are largely caused by abnormally elevated glucagon levels (Unger and Cherrington 2012).”
Association between vitamin A and D levels and the risk of type 1 diabetes mellitus in children
Rao, S., Li, T., Yan, Z., Li, X., Sun, W., Li, S., & Hou, L. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1837627 · Cited by 1
“Specifically, VA and its metabolites are key regulatory factors for maintaining the normal structure of the pancreas and the function of beta cells (39–41).”
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
Belani, J. D. (2026) · Nutrients · doi:10.3390/nu18152578 · Cited by 1
“Glucagon plays a complementary role by regulating hepatic glucose output [60,61].”
Lower glucagon response and attenuated hepatic glucagon signaling in MASLD
Kim, S. R., Hwang, Y., Lee, M., Choi, A., Lee, B., Kang, E. S., Cha, B., Kim, K. J., & Lee, Y. (2026) · Diabetes & Metabolism · doi:10.1016/j.diabet.2026.101787 · Cited by 1
Histopathology of the pancreas in fulminant type 1 diabetes after 23‐year follow‐up: a case report
Sato, T., Miki, T., Murakami, N., Hirohashi, Y., Kouzu, H., Furuhashi, M., Tanno, M., Yuda, S., Saitoh, S., Hasegawa, T., et al. (2012) · Pathology International · doi:10.1111/pin.12017 · Cited by 1
Kitaoka, S. (2015) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont) · Cited by 1
Glucagon Receptor Antagonist LGD-6972 Is Efficacious in Streptozotocin-Induced Diabetic Mice
Vajda, E. G., Zhi, L., & Marschke, K. B. (2013) · Cited by 1
Glukagon, das vergessene Hormon
Müller, T. D., & Tschöp, M. H. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0461-0 · Cited by 1
“Müller, alle Rechte vorbehalten) der Pathophysiologie des Typ-1-Diabetes der gesteigerten Aktivität von Glukagon eine größere Bedeutung zukommt als dem Mangel an Insulin [6, 7].”
BackgroundInfluentialGlucagon infusion alters the circulating metabolome and urine amino acid excretion in dogs
Merkhassine, M., Coch, R. W., Frederick, C. E., Bennett, L. L., Peng, S. A., Morse, B., Cummings, B. P., & Loftus, J. P. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0051 · Cited by 1
Role of glucagon in treating diabetes: Evidence and concepts (胰高血糖素在糖尿病治疗中的作用:证据与概念)
Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12107 · Cited by 1
“With fixed basal insulin levels, over the physiological range of hepatic sinusoidal glucagon from 0 to 200 pg/ mL, hepatic glucose production increases linearly from 0 to 5 mg/kg body weight per min, with a further doubling of hepatic glucose production possible with glucagon levels increasing above the physiological…”
BackgroundPiro, S., Urbano, F., Folli, F. B., Finzi, G., Marselli, L., & Marchetti, P. (2016) · Endocrinology · doi:10.1007/978-3-319-27318-1_31-1 · Cited by 1
Traitement du diabète de type 2. Où en sommes-nous des voies agissant sur le glucagon ?
Halimi, S., & Girard, J. R. (2018) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(18)30004-x · Cited by 1
Biomarkers of Insulin Resistance
Cox‐York, K. A., & Pereira, R. I. (2019) · Contemporary Endocrinology · doi:10.1007/978-3-030-25057-7_11 · Cited by 1
Biological Activities of Lasso Peptides and Structure–Activity Relationships
Li, Y., Zirah, S., & Rebuffat, S. (2014) · SpringerBriefs in microbiology · doi:10.1007/978-1-4939-1010-6_3 · Cited by 1
Nakamura, Y., Horie, I., Tashiro, S., Kobayashi, M., Kitamura, T., Kusunoki, Y., Nishida, K., Yamamoto, A., Hirota, Y., Fukui, T., et al. (2021) · Medicine Case Reports and Study Protocols · doi:10.1097/md9.0000000000000135 · Cited by 2
Piro, S., Urbano, F., Folli, F. B., Finzi, G., Marselli, L., & Marchetti, P. (2018) · Endocrinology · doi:10.1007/978-3-319-44675-2_31 · Cited by 1
Incretin Mimetics in the Indian Context: Revisiting Exenatide
Tripathi, S. K., Dasgupta, S., Joshi, S., Mukherjee, S., & Samajdar, S. S. (2022) · Bengal Physician Journal · doi:10.5005/jp-journals-10070-7073 · Cited by 1
Hvid, H., Brand, C. L., Hummelshøj, T., Jensen, S., Bouman, S. D., Bowler, A. N., Poulsen, B. R., Tiainen, P., Åkertröm, T., Demozay, D., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05828-w · Cited by 1
Іваненко, Т. В. (2023) · Current issues in pharmacy and medicine science and practice · doi:10.14739/2409-2932.2023.1.273223 · Cited by 1
“На нашу думку, таке зниження кількості с-kit позитивних альфа-клітин у щурів лінії SHR може свідчити про те, що ці зміни не стільки пов’язані з порушенням модуляції транскрипційного фактора NeuroD1/Β2, який реалізує стратегію диференціювання ембріональних ендокриноцитів в окремі лінії α- та b-клітин [19] чи активнішу…”
Small molecule glucagon release inhibitors with activity in human islets
Kalwat, M. A., Rodrigues-dos-Santos, K., Binns, D. D., Wei, S., Zhou, A., Evans, M. R., Posner, B. A., Roth, M. G., & Cobb, M. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1114799 · Cited by 1
Double et triple agonistes : rôle du glucagon
Scheen, A. J. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.06.006 · Cited by 2
Gut hormones — Team workers or solo trippers?
Rehfeld, J. F. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.03.003 · Cited by 1
The Challenge of Predicting Future Blood Glucose for Patients with Type I Diabetes
Borle, N. C. (2018) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3dv1d378 · Cited by 1
“Given our belief that training more accurate models will require additional relevant variables, future research might incorporate more confounding variables, such as injection location [20], glucagon levels [40] and/or meal protein content [28].”
BackgroundTrefts, E. (2019) · Cited by 1
5: Diabetes Secondary to Endocrinopathies
Silverstein, J. M., Sterl, K., Cartier, J. L., Cruz‐Bravo, P., Davis, C., Sadiq, S., & McGill, J. B. (2018) · American Diabetes Association eBooks · doi:10.2337/9781580406666.05 · Cited by 1
Vanweert, F. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231117fv · Cited by 1
Lee, J., Ustione, A., Wilkerson, E., Balakrishnan, R., Thurmond, D. C., Goldfarb, D., & Piston, D. W. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.30.610490 · Cited by 1
Faggionato, E., Tonello, A., Laurenti, M. C., Vella, A., & Dalla Man, C. (2025) · American Journal of Physiology - Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00172.2025
Beshyah, S., & Deeb, A. (2012) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/1947-489x.210784 · Cited by 1
The role of Arx in specification and maintenance of pancreatic islet alpha-cells
Wilcox, C. L. (2013) · ScholarlyCommons (University of Pennsylvania)
Insulin-like growth factor -I deficiency, insulin sensitivity, and glucose metabolism
Ekström, K. (2013) · Figshare
Glucagon, physiologie et physiopathologie
Mouly, C. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2012.11.012
A cistrome roadmap for understanding pancreatic islet biology
Avrahami, D., & Kaestner, K. H. (2014) · Nature Genetics · doi:10.1038/ng.2880
Ishihara, H. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.3237
Metadata
- Authors
- Unger, R. H., & Cherrington, A. D.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Vanderbilt University (US)
- Corresponding author
- Unger, Roger H.
- ORCID
- Cherrington, Alan D.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-01-03
- Volume
- 122
- Issue
- 1
- Pages
- 4-12
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3248306
- OpenAlex
- W2113278846
- Cited by
- 670
- References
- 100
- Citations by year
- 2026: 30 · 2025: 28 · 2024: 38 · 2023: 41 · 2022: 36 · 2021: 46 · 2020: 45 · 2019: 48 · 2018: 68 · 2017: 54 · 2016: 49 · 2015: 56 · 2014: 57 · 2013: 48 · 2012: 26
- FWCI
- 11.54
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Amylin Pharmaceuticals
- University of Texas Southwestern Medical Center
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, hyperglucagonemia, diabetes pathophysiology, insulin deficiency, hepatic glucose production, ketogenesis, leptin, somatostatin, glucagon receptor, pancreatic beta cells, alpha cells, anti-insulin serum
- MeSH terms
- Animals, Diabetes Mellitus, Type 1, Glucagon, Humans, Insulin, Liver, Pancreas, Glycogenolysis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.